K. Govind Babu

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

K. Park, Johan Vansteenkiste, Ki Hyeong Lee et al. · Annals of Oncology · 2020 · 111 citations · Full text

Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: A randomized, open-label, phase IIb, 5-year study in Indian patients

Balaswamy Reddy, V. Lokesh, M. S. Vidyasagar et al. · Oral Oncology · 2014 · 109 citations

Indian Patients, Oncology, Neoadjuvant Therapy +10

Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial

Jörge E. Cortes, Cármino Antônio De Souza, Manuel Ayala et al. · The Lancet Haematology · 2016 · 40 citations · Full text

Chronic Phase, Open-label Trial, Hematological Malignancy +11

Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1

Eugen Tausch, Philipp Beck, Richard F. Schlenk et al. · Haematologica · 2020 · 38 citations · Full text

Chronic Lymphocytic Leukemia, Mixed-phenotype Acute Leukemia, Immunology +18

An open-label, randomized, study of h-R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): Four-year survival results from a phase IIb study.

K. Govind Babu, Lokesh Viswanath, Balaswamy Reddy et al. · Journal of Clinical Oncology · 2010 · 37 citations

Squamous Cell Carcinoma, Pathology, Crt+h-r3mab Arm +20